The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), and the University of Queensland’s (UQ) Community for Open Antimicrobial Drug Discovery (CO-ADD) in its efforts to develop and ensure new antibiotics are globally available to all patients who need them.

The agreement allows GARDP to access and test Calibr’s ReFRAME compound library and HIPS natural products library. Both libraries will be screened by CO-ADD to discover novel compounds or combinations of drugs that will kill the priority pathogens identified by the World Health Organization in critical need for research and development of new antibiotics.

This is GARDP’s first discovery collaboration that links partners in Germany and the USA with Australia. Through this screening, GARDP seeks to identify novel compounds suitable for optimization and clinical development as drugs for patients.